Abstract: Provided are a CD19-targeting chimeric antigen receptor and use thereof. Further provided are a CD19-targeting chimeric antigen receptor, a corresponding nucleic acid molecule, a vector, an immune effector cell, a preparation method therefor, a product thereof, a pharmaceutical composition, a therapeutic use, a pharmaceutical use, and a tumor or cancer treatment method.

Abstract: Deflection spring compression mounting is disclosed. A disclosed example deflection spring for an electronics package includes first and second end portions having first and second locking interfaces, respectively, to at least partially constrain the first and second end portions relative to a support, a curved portion, and a medial portion having a third locking interface to fix the medial portion relative to the support, wherein fixing the medial portion relative to the support causes the curved portion to contact and press against the electronics package.

Abstract: Herein, we provide genetically engineered immune effector cells, among other cells, which express CAR and secret a bispecific “trap” protein co-targeting a checkpoint protein and TGF-? or TGF-? receptor, so as to improve the antitumor immunity of the immune effector cells. Compared with conventional CAR-T cells and CAR-T cells secreting a polypeptide checkpoint inhibitor, the provided genetically engineered immune effector cells CAR-T cells with “trap” protein secretion attenuate inhibitory T cell signaling, enhance T cell persistence and expansion, and improve effector functionalities and resistance to exhaustion. In a xenograft mouse model, CAR-T cells with “trap” protein secretion significantly enhanced antitumor immunity and efficacy. Methods of using these genetically engineered cells, as well as using polynucleotides encoding the CAR and the “trap” protein, are also provided, for example, as a therapy against solid tumors.

Abstract: Provided is a self-assembling peptide, a preparation method, the self-assembling peptide formulations and use, and it is related to the field of biotechnology. The self-assembling peptide provided by the present disclosure has a general formula as shown in AC-Pro-X1-X3-X2-X3-X1-X3-X2-Pro-amide. Through experiments, the inventors of the present disclosure found that the self-assembling peptide provided by the present disclosure, because solubility is high and difficulty of synthesis and purification is less compared with a traditional self-assembling peptide, is more feasible for industrial production, and even cheaper to produce. In mass synthesis and purification, the number of purification decreases, the single purification amount increases, the purity of a crude peptide can reach 90% or more, and the cost is greatly reduced.

Abstract: Aspects of the present disclosure relate to methods and compositions related to the preparation of immune cells, including engineered immune cells. Certain embodiments of the disclosure include compositions, cells, and methods related to engineered invariant natural killer T (iNKT) cells for off-the-shelf use for clinical therapy. The iNKT cells may be produced from hematopoietic stem progenitor cells and may be suitable for allogeneic cellular therapy because they are HLA negative. In some aspects, the cells have imaging and suicide targeting capabilities.

Abstract: The present disclosure is directed towards genetically engineered TCR-T cells to recognize tumor antigens and simultaneously secrete a binding protein that blocks an immune checkpoint molecule and TGF-beta. These engineered T cells demonstrate stronger antitumor response and reduced T cell exhaustion. The present disclosure provides immunotherapy against HPV- or EBV-positive cancers, among others.

Abstract: Due to potential sampling errors (due to small tissue samples not necessarily directly from the developing tumor) and limited optical resolution (˜1 micron), cancer may be missed or detected too late for optimal treatment, or conservative interpretation of indeterminate findings could lead to unnecessary surgery. The novel technology herein—Spatial-domain Low-coherence Quantitative Phase Microscopy (SL-QPM)—can detect structural alterations within cell nuclei with nanoscale sensitivity (0.9 nm) (or nuclear nano-morphology) for “nano-pathological diagnosis” of cancer. SL-QPM uses original, unmodified cytology and histology specimens prepared with standard clinical protocols and stains. SL-QPM can easily integrate in existing clinical pathology laboratories. Results quantified the spatial distribution of optical path length or refractive index in individual nuclei with nanoscale sensitivity, which could be applied to studying nuclear nano-morphology as cancer progresses.

Abstract: Described herein are compositions a genetically modified comprising nucleic acids encoding a chimeric antigen receptor (CAR) and a checkpoint inhibitor and methods for using the compositions to treat cancer.

Abstract: The invention is directed to a masked chimeric antigen receptor, comprising: (a) a masking peptide; (b) one or more antigen-specific targeting domains; (c) an extracellular spacer domain; (d) a transmembrane domain; (e) at least one co-stimulatory domain; and (f) an intracellular signaling domain. The mCARs are activated upon cleavage of the masking peptide.

Abstract: Methods and compositions are provided for delivery of a polynucleotide encoding a gene of interest, typically an antigen, to a dendritic cell (DC). The virus envelope comprises a DC-SIGN specific targeting molecule. The methods and related compositions can be used to treat patients suffering from a wide range of conditions, including infection, such as HIV/AIDS, and various types of cancers.

Abstract: Compositions are provided including NK cells that express chimeric antigen receptors (CARs) specific to CD19 and Her2 and a plurality of cell surface-bound multilamellar liposomal vesicles loaded with one or more anti-cancer therapeutics at an effective amount for inhibiting or killing tumor cells without causing toxicity to the NK cells. Methods of using these compositions to treat a subject with tumor are also provided, including administering an effective amount of the CAR-engineered NK cells, where an effective amount of anti-tumor therapeutics are delivered in particles (e.g., crosslinked multilamellar liposomal vesicles) that are bound to the surface of these CAR-engineered NK cells, without causing toxicity to the carrier NK cells.

Abstract: The present invention generally relates to engineered cells and compositions thereof, particularly, T cells comprising genetically engineered T Cell receptors (TCRs) and checkpoint inhibitors (CPIs). Methods for using the compositions to treat cancer are also disclosed herein. Genetically engineered T cells that recognize tumor antigen HPV E6 and simultaneously secrete a single-chain antibody that blocks Programmed Cell Death Protein 1 (PD-1). Also provided is an immunotherapy for HPV E6 expression related cancers.

Abstract: A vehicle-mounted charger having voice control function includes: a contact plug, a charging socket, a voice acquisition unit, a recognition control unit, and a first BLUETOOTH unit. The voice acquisition unit collects a voice signal and converts the voice signal to an electrical signal. The recognition control unit includes a conversion module, a first storage module, an operation module, and an executive module. The conversion module converts the electrical signal into a data signal and sends the data signal to the operation module. The operation module compares the data signal with predetermined storage data stored by the first storage module, operates the data signal, and sends control command to the executive module. The executive module sends executive command according to the control command. The first BLUETOOTH unit sends BLUETOOTH signal to the portable device according to the executive command to control the portable device to execute corresponding operation.

Abstract: Described herein are compositions including an immune effector cells that are chemically modified at the surface with one or more active agent-loaded nano- or micro-particles for controlled release of the active agent. Exemplary drug-loaded nanoparticles include crosslinked multilayer liposome (CMLV) encapsulating an A2a receptor inhibitor. The modified immune effector cells may also present one or more chimeric antigen receptors (CARs) on the surface. Also provided are methods of using the same to treat cancer.

Abstract: Methods and compositions are provided for delivery of a polynucleotide encoding a gene of interest, typically an antigen, to a dendritic cell (DC). The virus envelope comprises a DC-SIGN specific targeting molecule. The methods and related compositions can be used to treat patients suffering from a wide range of conditions, including infection, such as HIV/AIDS, and various types of cancers.

Abstract: Methods and compositions are provided for delivery of a polynucleotide encoding a gene of interest, typically an antigen, to a dendritic cell (DC). The virus envelope comprises a DC-SIGN specific targeting molecule. The methods and related compositions can be used to treat patients suffering from a wide range of conditions, including infection, such as HIV/AIDS, and various types of cancers.

Abstract: The present invention provides for a library or an array of two or more nucleic acids encoding portions of genes selected from a set of 27 genes which are useful for predicting lung cancer survival, and a method for predicting a subject's overall survival (OS) from a lung cancer using two or more genes selected from the set of 27 genes.

Abstract: Disclosed is use of a panel of gastric cancer (GC)-related genes in clinical applications. The present invention is based on a panel of 53 genes related to prognosis in GC and detection of their expression levels in clinical samples to calculate prognostic scores, so as to evaluate clinical prognosis of GC patients and its other applications. This score system is useful for assisting in treatment selection for GC patients and predicting the response to therapeutic intervention, to determine the degree of benefit of patients from chemotherapy and targeted therapy, thus avoiding overtreatment, reducing medical cost, and achieving personalized medicine. Accordingly, a 53-gene expression assay kit is designed and developed according to this system and different detection technology platforms.

Abstract: Methods and compositions are provided for delivery of a polynucleotide encoding a gene of interest, typically an antigen, to a dendritic cell (DC). The virus envelope comprises a DC-SIGN specific targeting molecule. The methods and related compositions can be used to treat patients suffering from a wide range of conditions, including infection, such as HIV/AIDS, and various types of cancers.

Abstract: Methods and compositions are provided for delivering a polynucleotide encoding a gene of interest to a target cell using a virus. The virus envelope comprises a cell-specific binding determinant that recognizes and binds to a component on the target cell surface, leading to endocytosis of the virus. A separate fusogenic molecule is also present on the envelope and facilitates delivery of the polynucleotide across the membrane and into the cytosol of the target cell. The methods and related compositions can be used for treating patients having suffering from a wide range of conditions, including infection, such as HIV; cancers, such as non-Hodgkin's lymphoma and breast cancer; and hematological disorders, such as severe combined immunodeficiency.